SCHEMBL2899157

SCHEMBL2899157

N=C(N)NCCC[C@H](N)C(=O)OC[C@H](N)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OTC P00480 1/20 0.43
DDAH1 O94760 4/20 0.41
NOS2 P35228 5/20 0.39
NOS3 P29474 4/20 0.39
NOS1 P29475 4/20 0.39
GSR P00390 1/20 0.36
NPY4R P50391 3/20 0.36
NPY1R P25929 1/20 0.36
CYP2C19 P33261 2/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
APEX1 P27695 1/20 0.36
IDO1 P14902 1/20 0.35
DPP7 Q9UHL4 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NOD1 Q9Y239 1/20 0.34
ARG1 P05089 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL26980027 0.92 GSR (0.46) OTCDDAH1NOS2NOS3NOS1
SCHEMBL6535302 0.90 GSR (0.45) OTCDDAH1NOS2NOS3NOS1
SCHEMBL18877225 0.86 NPY4R (0.36) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL1790 0.85 OTC (0.56) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL288132 0.85 OTC (0.56) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL29518651 0.85 OTC (0.56) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL6374054 0.85 OTC (0.56) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL7928810 0.85 OTC (0.56) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL2411547 0.85 OTC (0.56) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL1791 0.85 OTC (0.56) OTCDDAH1NOS2NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210251963-A1 UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 SCANDION ONCOLOGY A/S (DK) 2021-08-19 US claimed
EP-3846802-A1 UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 Scandion Oncology A/S (DK) 2021-07-14 EP claimed
US-8475792-B2 Molecules with extended half-lives, compositions and uses thereof MEDIMMUNE, LLC (US) 2013-07-02 US claimed
EP-1588173-A2 AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS Carlsberg A/S (DK) 2005-10-26 EP claimed
WO-2004062553-A2 AFFINITY SCREENING USING “ONE-BEAD-ONE-COMPOUND” LIBRARIES CARLSBERG A/S (DK) 2004-07-29 WO claimed
US-20040142379-A1 Affinity fishing for ligands and proteins receptors CARLSBERG RESEARCH LABORATORY (DK) 2004-07-22 US claimed
WO-2003099322-A2 IL-11 DERIVATIVES AND THERAPEUTIC USES THEREOF ISIS INNOVATION LIMITED (GB) 2003-12-04 WO claimed
EP-0828002-B1 Modification of xylanase to improve thermophilicity, alkophilicity and thermostability CA NAT RESEARCH COUNCIL (CA) 2002-04-17 EP claimed
CN-114149432-B Dual CLK/CDK1 inhibitors for cancer treatment 斯坦福国际研究院 2024-07-05 CN disclosed
US-11964971-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2024-04-23 US disclosed
CN-117327714-B Australian wild cotton splicing factor GauSR45a and application thereof 南京农业大学三亚研究院 2024-03-01 CN disclosed
US-11866705-B2 Small cell lung cancer therapeutic agent containing oligonucleotide Osaka Univerity (JP) 2024-01-09 US disclosed
CN-117327714-A Australian wild cotton splicing factor GauSR45a and application thereof 南京农业大学三亚研究院 2024-01-02 CN disclosed
US-11858897-B2 Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-02 US disclosed
EP-1663219-A2 USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-06-07 EP disclosed
EP-1588173-A2 AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS Carlsberg A/S (DK) 2005-10-26 EP disclosed
CN-1657539-A Human connective tissue growth factor mutant protein and its application MEDICAL BIOGOGICAL INST CHINA (CN) 2005-08-24 CN disclosed
WO-2005023255-A2 USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2005-03-17 WO disclosed
WO-2004062553-A2 AFFINITY SCREENING USING “ONE-BEAD-ONE-COMPOUND” LIBRARIES CARLSBERG A/S (DK) 2004-07-29 WO disclosed
WO-1996030398-A1 NOVEL AUTO ANTIGEN MURDOCH UNIVERSITY (AU) 1996-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964971-B2 Methods and compositions for modulating splicing RBM17, SF3B1, SF3B5 OTC 4185/4885DDAH1 2142/4885NOS2 2388/4885
US-20210251963-A1 UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 SRPK1, SRPK3, HNRNPK OTC 554/4885DDAH1 1947/4885NOS2 2254/4885
US-11858897-B2 Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK SRPK3, SRPK1, SRPK2 OTC 3023/4885DDAH1 3305/4885NOS2 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.